Adherence in the Treatment of HIV and Other Infectious Diseases

  • Karen Moore Goldstein


Over the last decade, survival in patients with human immunodeficiency virus (HIV) has lengthened dramatically due to improvements in the robust options for antiretroviral therapy (ART) [1]. Clinicians caring for HIV-positive patients now face many of the same challenges encountered by those with other chronic conditions (e.g., cardiovascular disease, complications from diabetes, aging) [2]. One particular issue that plagues all clinicians caring for patients with chronic diseases is how to promote optimal adherence to prescribed treatment over time. Adherence to treatment for HIV has some unique features that make its assessment and measurement challenging. In this chapter, we will review the ways in which this disease differs from and is similar to other chronic diseases. Lastly, we will identify methods and techniques that clinicians may use to enhance adherence among individuals with HIV. Of note, we will be specifically focusing on issues pertaining to the treatment of HIV in the USA.


Human Immunodeficiency Virus Sexually Transmit Infection Adherence Intervention Virologic Failure Virologic Suppression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



I would like to acknowledge the helpful input and guidance of Dr. Karam Mounzer in the development of this chapter, as well as Jeremy Goldstein for assistance with images and layout.


  1. 1.
    CDC. HIV and AIDS in the United States: A picture of today’s epidemic. 2008. Available at: Accessed January 9, 2009.
  2. 2.
    Gifford AL, Groessl EJ. Chronic disease self-management and adherence to HIV medications. J Acquir Immune Defic Syndr. 2002;31:S163–S166.PubMedCrossRefGoogle Scholar
  3. 3.
    Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008;1–139. Available at:
  4. 4.
    Gross R, Bilker W, Friedman H, et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109–2117.PubMedCrossRefGoogle Scholar
  5. 5.
    Ickovics J, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antiviral Ther. 2002;7:185–193.Google Scholar
  6. 6.
    Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–1121.PubMedCrossRefGoogle Scholar
  7. 7.
    Press N, Tyndall M, Wood E, et al. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31:S112–S117.PubMedCrossRefGoogle Scholar
  8. 8.
    Perno CR, Ceccherini-Silberstein F, De Luca A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr. 2002;31:S118–S122.PubMedCrossRefGoogle Scholar
  9. 9.
    Vrijens B, Urquhart J. Patient adherence to prescribed antimicrovial drug dosing regimens. J Antimicrob Chemother. 2005;55:616–627.PubMedCrossRefGoogle Scholar
  10. 10.
    Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197:S272–S278.PubMedCrossRefGoogle Scholar
  11. 11.
    Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307–311.PubMedCrossRefGoogle Scholar
  12. 12.
    Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–394.PubMedCrossRefGoogle Scholar
  13. 13.
    Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr. 2006;41:439–446.PubMedCrossRefGoogle Scholar
  14. 14.
    Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051–1058.PubMedCrossRefGoogle Scholar
  15. 15.
    El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.PubMedCrossRefGoogle Scholar
  16. 16.
    DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS. 2008;22:237–247.CrossRefGoogle Scholar
  17. 17.
    Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38:1311–1316.PubMedCrossRefGoogle Scholar
  18. 18.
    Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 1999;13:1099–1107.PubMedCrossRefGoogle Scholar
  19. 19.
    Nieuwkerk PT, Sprangers MAG, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161:1962–1968.PubMedCrossRefGoogle Scholar
  20. 20.
    Tam LWY, Chui CKS, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr. 2008;49:266–271.PubMedCrossRefGoogle Scholar
  21. 21.
    Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–941.PubMedCrossRefGoogle Scholar
  22. 22.
    Golin C, Liu H, Hays R, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756–765.PubMedCrossRefGoogle Scholar
  23. 23.
    Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003;17:1925–1932.PubMedCrossRefGoogle Scholar
  24. 24.
    Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMedGoogle Scholar
  25. 25.
    Kalichman SC, Amaral CM, Stearns H, et al. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med. 2007;22:1003–1006.PubMedCrossRefGoogle Scholar
  26. 26.
    Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients’ adherence to combination antiretroviral therapy? J Gen Intern Med. 2002;17:1–11.PubMedCrossRefGoogle Scholar
  27. 27.
    Gross R, Yip B, Lo Re V, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108–1114.PubMedCrossRefGoogle Scholar
  28. 28.
    Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124–133.PubMedCrossRefGoogle Scholar
  29. 29.
    Ickovics J, Meade C. Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr. 2002;31:S98–S102.PubMedCrossRefGoogle Scholar
  30. 30.
    Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31:S123–S127.PubMedCrossRefGoogle Scholar
  31. 31.
    Sidat M, Fairley C, Grierson J. Experiences and perceptions of patients with 100% adherence to highly active antiretroviral therapy: a qualitative study. AIDS Patient Care and STDs. 2007;21:509–520.PubMedCrossRefGoogle Scholar
  32. 32.
    Arnsten JH, Li X, Mizuno Y, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Defic Syndr. 2007;46:S64–S71.PubMedCrossRefGoogle Scholar
  33. 33.
    Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–381.PubMedGoogle Scholar
  34. 34.
    Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care. 2004;16:199–211.PubMedCrossRefGoogle Scholar
  35. 35.
    Goujard C, Bernard N, Sohier N, et al. Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003;34:191–194.PubMedCrossRefGoogle Scholar
  36. 36.
    Falagas ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology. 2008;5:13.PubMedCrossRefGoogle Scholar
  37. 37.
    Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46:93–108.PubMedCrossRefGoogle Scholar
  38. 38.
    Trotta MP, Ammassari A, Melzi S, et al. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31:S128–S131.PubMedCrossRefGoogle Scholar
  39. 39.
    Viciana P, Rubio R, Ribera E, et al. Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study). Enferm Infecc Microbiol Clin. 2008;26:127–134.PubMedCrossRefGoogle Scholar
  40. 40.
    Smith SR, Rublein JC, Marcus C, et al. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns. 2003;50:187–199.PubMedCrossRefGoogle Scholar
  41. 41.
    Bangsberg DR, Bronstone A, Hofman R. A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care. 2002;14:3–15.PubMedCrossRefGoogle Scholar
  42. 42.
    Murri R, Ammassari A, Nappa S, et al. Physician estimates of adherence and the patient-physician relationship as a setting to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:S158–S162.PubMedCrossRefGoogle Scholar
  43. 43.
    Kidder DP, Wolitski RJ, Campsmith ML, et al. Health status, health care use, medication use, and medication adherence among homeless and housed people living with ENDS. Am J Public Health. 2007;97:2238–2245.PubMedCrossRefGoogle Scholar
  44. 44.
    Leaver CA, Bargh G, Dunn JR, et al. The effects of housing status on health-related outcomes in people living with HIV: a systematic review of the literature. AIDS Behav. 2007;11:S85–S100.CrossRefGoogle Scholar
  45. 45.
    Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35:305–312.PubMedCrossRefGoogle Scholar
  46. 46.
    Binswanger IA, Stern MF, Deyo RA, et al. Release from prison – A high risk of death for former inmates. N Engl J Med. 2007;356:157–165.PubMedCrossRefGoogle Scholar
  47. 47.
    Robison LS, Westfall AO, Mugavero MJ, et al. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses. 2008;24:1347–1355.PubMedCrossRefGoogle Scholar
  48. 48.
    Gross R, Zhang Y, Grossberg R. Medication refill logistics and refill adherence in HIV. Pharmacoepidemiol Drug Safety. 2005;14:789–793.CrossRefGoogle Scholar
  49. 49.
    Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care. 2006;18:853–861.PubMedCrossRefGoogle Scholar
  50. 50.
    Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43:S79–S87.PubMedCrossRefGoogle Scholar
  51. 51.
    Mounzer, K. Choosing an optimal second-line regimen for a patient with intermittent adherence [Clinical care options web site]. 2008. Available at: Accessed January 9, 2009.
  52. 52.
    Glass TR, De Geest S, Hirschel B, et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antiviral Ther. 2008;13:77–85.Google Scholar
  53. 53.
    Kaplan S, Mounzer K. Antiretroviral therapy in HIV-infected patients with multidrug-resistant virus: applying the guidelines to practice. AIDS Patient Care STDs. 2008;22:931–940.PubMedCrossRefGoogle Scholar
  54. 54.
    Kredo T, Van der Walt J, Siegfried N, et al. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev. 2008; (Issue 3). Art. No.: CD007268. DOI:10.1002/14651858.CD007268.Google Scholar
  55. 55.
    Dolin R, Masur H, Saag M. AIDS therapy. Philadelphia, PA: Churchill Livingstone; 1999.Google Scholar
  56. 56.
    Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004;5:201–205.PubMedCrossRefGoogle Scholar
  57. 57.
    Petersen K, Riddle MS, Jones LE, et al. Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy. AIDS. 2005;19:1700–1702.PubMedCrossRefGoogle Scholar
  58. 58.
    Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43:S149–S155.PubMedCrossRefGoogle Scholar
  59. 59.
    Simoni JM, Pearson C, Pantalone D, et al. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load: a meta-analytic Review of Randomized Controlled Trials. J Acquir Immune Defic Syndr. 2006;43:S23–S35.PubMedCrossRefGoogle Scholar
  60. 60.
    Rueda S, Park-Wyllie L, Bayoumi A, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev. 2006; (Issue 3). Art. No.: CD001442.DOI:10.1002/14651858.CD001442.pub2.Google Scholar
  61. 61.
    Amico KR, Harman J, Johnson B. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996–2004. J Acquir Immune Defic Syndr. 2006;41:285–297.PubMedCrossRefGoogle Scholar
  62. 62.
    Simoni J, Frick P, Pantalone D, et al. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Topics HIV Med. 2003;11:185–198.Google Scholar
  63. 63.
    Jones DL, McPherson-Baker S, Lydston D, et al. Efficacy of a group medication adherence intervention among HIV positive women: The SMART/EST women’s project. AIDS Behav. 2007;11:79–86.PubMedCrossRefGoogle Scholar
  64. 64.
    Jones DL, Ishii M, LaPerriere A, et al. Influencing medication adherence among women with AIDS. AIDS Care. 2003;15:463–474.PubMedCrossRefGoogle Scholar
  65. 65.
    Rawlings MK, Thompson M, Farthing C, et al. Impact of an educational program on efficacy and adherence with a twice-daily Lamivudine/Zidovudine/Abacavir regimen in underrepresented HIV-infected patients. J Acquir Immune Defic Syndr. 2003;34:174–183.PubMedCrossRefGoogle Scholar
  66. 66.
    Wagner G, Kanouse D, Golinelli D, et al. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS. 2006;20:1295–1302.PubMedCrossRefGoogle Scholar
  67. 67.
    Golin C, Earp J, Tien H-C, et al. A 2-Arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J Acquir Immune Defic Syndr. 2006;42:42–51.PubMedCrossRefGoogle Scholar
  68. 68.
    DiIorio C, McCarty F, Resnicow K, et al. Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. Aids Care. 2008;20:273–283.PubMedCrossRefGoogle Scholar
  69. 69.
    Tuldra A, Fumaz C, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:221–228.PubMedCrossRefGoogle Scholar
  70. 70.
    Pradier C, Bentz L, Spire B, et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials. 2003;4:121–131.PubMedCrossRefGoogle Scholar
  71. 71.
    Reynolds N, Testa M, Su M, et al. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. J Acquir Immune Defic Syndr. 2008;47:62–68.PubMedCrossRefGoogle Scholar
  72. 72.
    Mannheimer S, Morse E, Matts J, et al. Sustained benefit from a long-term antiretroviral adherence intervention: results of a large randomized clinical trial. J Acquir Immune Defic Syndr. 2006;43:S41–S47.PubMedCrossRefGoogle Scholar
  73. 73.
    Safren SA, Hendriksen ES, Desousa N, et al. Use of an on-line pager system to increase adherence to antiretroviral medications. AIDS Care. 2003;15:787–793.PubMedCrossRefGoogle Scholar
  74. 74.
    Andrade A, McGruder H, Wu A, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis. 2005;41:875–882.PubMedCrossRefGoogle Scholar
  75. 75.
    Wise J, Operario D. Use of electronic reminder devices to improve adherence to antiretroviral therapy: a systematic review. AIDS Patient Care STDs. 2008;22:495–504.PubMedCrossRefGoogle Scholar
  76. 76.
    Petersen M, Wang Y, van der Laan M, et al. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007;45:908–915.PubMedCrossRefGoogle Scholar
  77. 77.
    Lucas G, Flexner C, Moore R. Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? AIDS Patient Care STDs. 2002;16:527–535.PubMedCrossRefGoogle Scholar
  78. 78.
    Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34:511–518.PubMedCrossRefGoogle Scholar
  79. 79.
    Babudieri S, Aceti A, D’Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000;284:179–180.PubMedCrossRefGoogle Scholar
  80. 80.
    Lucas G, Mullen A, Weidle P, Hader S, McCaul M, Moore R. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42:1628–1635.PubMedCrossRefGoogle Scholar
  81. 81.
    Altice FL, Maru D, Bruce RD, Springer S, Friedland G. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45:770–778.PubMedCrossRefGoogle Scholar
  82. 82.
    Levy RW, Rayner CR, Fairley CK, et al. Multidisciplinary HIV adherence intervention: a randomized study. Aids Patient Care and Stds 2004;18:728–735.PubMedCrossRefGoogle Scholar
  83. 83.
    Safren SA, Boswell S, Johnson W, Salomon L, Mayer K. Initial outcome of an on-line paging system (Medimom) to increase adherence to antiretroviral medications. In: Conference on Retroviruses and Opportunistic Infections. Chicago, IL; 2001:Abstract No. 480.Google Scholar
  84. 84.
    Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet. 1999;353:1657–1661.PubMedCrossRefGoogle Scholar
  85. 85.
    Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921–929.PubMedCrossRefGoogle Scholar
  86. 86.
    Freedberg KA, Hirschhorn LR, Schackman BR, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;43:S113–S118.PubMedCrossRefGoogle Scholar
  87. 87.
    Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115:632–641.PubMedCrossRefGoogle Scholar
  88. 88.
    Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817–823.PubMedCrossRefGoogle Scholar
  89. 89.
    Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824–831.PubMedCrossRefGoogle Scholar
  90. 90.
    ADAP programs fight for survival with less money and more clients. North Carolina’s list tops 700 by midyear. AIDS Alert. 2004;19:85, 7–9.Google Scholar
  91. 91.
    More patients seek drugs through ADAPs, creating $50 million deficit. AIDS Alert. 2001;16:53–56.Google Scholar
  92. 92.
    CDC. reported tuberculosis in the United States, 2007. 2008. Available at: Accessed on January 9, 2009.
  93. 93.
    Horsburgh CR, Feldman S, Ridzon R. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis. 2000;31:633–639.PubMedCrossRefGoogle Scholar
  94. 94.
    Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis – consensus statement of the public health tuberculosis guidelines panel. J Am Med Assoc. 1998;279:943–948.CrossRefGoogle Scholar
  95. 95.
    Hirsch-Moverman Y, Daftary A, Franks J, et al. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tubercular Lung Dis. 2008;12:1235–1254.Google Scholar
  96. 96.
    Burman WJ, Cohn DL, Rietmeijer CA, et al. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest. 1997;111:1168–1673.PubMedCrossRefGoogle Scholar
  97. 97.
    Blumberg HM, Burman WJ, Chaisson RE, et al. American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–662.PubMedCrossRefGoogle Scholar
  98. 98.
    Franke MF, Appleton SC, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 2008;46:1844–1851.PubMedCrossRefGoogle Scholar
  99. 99.
    Pozsik C, Kinney J, Breeden D, et al. Approaches to Improving Adherence to Antituberculosis Therapy – South Carolina and New York, 1986–1991. Morb Mortal Wkly Rev. 1993;42:74–75, 81.Google Scholar
  100. 100.
    Liu Q, Abba K, Alejandria M, et al. Reminder systems and late patient tracers in the diagnosis and management of tuberculosis. Cochrane Database Syst Rev. 2008:Art. No.:CD006594. DOI: 10.1002/14651858.CD006594.pub2.Google Scholar
  101. 101.
    Jasmer R, Seaman C, Gonzalez L, et al. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med. 2004;170:561–566.PubMedCrossRefGoogle Scholar
  102. 102.
    Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database of Syst Rev. 2007:Art. No.: CD003343. DOI: 10.1002/14651858.CD003343.pub3.Google Scholar
  103. 103.
    Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug-resistance and relapse in tuberculosis. N Engl J Med. 994;330:1179–1184.Google Scholar
  104. 104.
    Augenbraun M, Bachmann L, Wallace T, et al. Compliance with doxycycline therapy in sexually transmitted diseases clinics. Sex Transm Dis. 1998;25:1–4.PubMedCrossRefGoogle Scholar
  105. 105.
    Katz BP, Zwickl BW, Caine VA, et al. Compliance with antibiotic therapy for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis. 1992;19:351–354.PubMedCrossRefGoogle Scholar
  106. 106.
    Reyes H, Guiscafre H, Munoz O, et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol. 1997;50:1297–1304.PubMedCrossRefGoogle Scholar
  107. 107.
    Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49:897–903.PubMedCrossRefGoogle Scholar
  108. 108.
    Bachmann LH, Stephens J, Richey CM, et al. Measured versus self-reported compliance with doxycycline therapy for Chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis. 1999;26:272–278.PubMedCrossRefGoogle Scholar
  109. 109.
    Alexiou Z, Mouktaroudi M, Koratzanis G, et al. The significance of compliance for the success of antimicrobial prophylaxis in recurrent lower urinary tract infections: the Greek experience. Int J Antimicrob Agen. 2007;30:40–43.CrossRefGoogle Scholar
  110. 110.
    Wright J, Htun Y, Leong G, et al. Evaluation of the use of calendar blister packaging on patient compliance with STD Syndromic Treatment Regimens. Sex Transm Dis. 1999;26:556–563.PubMedCrossRefGoogle Scholar
  111. 111.
    Beaucage K, Lachance-Demers H, Ngo TT, et al. Telephone follow-up of patients receiving antibiotic prescriptions from community pharmacies. Am J Health Sys Pharm. 2006;63:557–563.CrossRefGoogle Scholar
  112. 112.
    Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–674.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of General Internal MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations